Clinical trial

Omega-3 Fatty Acids Efficacy in First-episode of Schizophrenia

NCT02210962

Drugs and interventions used in this trial

2 registered

These interventions are listed by ClinicalTrials.gov. An RxNorm link indicates a mapped medicine record; the registry name alone is not proof of a specific branded formulation.

Search this trial's interventions

DIETARY_SUPPLEMENT · Unmapped registry intervention essential fatty acids Find medicine records · Find other trials using this name

DIETARY_SUPPLEMENT · Unmapped registry intervention olive oil Find medicine records · Find other trials using this name

Study at a glance

Registry-backed

Omega-3 Fatty Acids Efficacy in First-episode of Schizophrenia

Design: INTERVENTIONAL · Status: UNKNOWN · Phase: PHASE4

Read study objectives, eligibility and outcome measures at ClinicalTrials.gov

StatusUNKNOWN

Study typeINTERVENTIONAL

Start date2011-09-01

PhasePHASE4

Conditions

Schizophreniaverified · MONDO: schizophrenia

Interventions

essential fatty acidsDIETARY_SUPPLEMENT

olive oilDIETARY_SUPPLEMENT

Sponsors & collaborators

Medical University of Lodzlead sponsor

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT02210962 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.